The Call for Opposition: Challenging the P2P and IOM Processes
In our second article on how to react to the publication of the draft P2P report, Gabby Klein provides her view of why she and a large group of advocates and patients are continuing their protest of the government’s ongoing control and manipulation of our disease via their processes...
Discuss the article on the Forums.

Rituxan will be off patent in 2013 in Europe

Discussion in 'Rituximab: News and Research' started by fairlight, Jul 30, 2012.

  1. fairlight

    fairlight

    Messages:
    77
    Likes:
    0
  2. August59

    August59 Daughters High School Graduation

    Messages:
    1,563
    Likes:
    516
    Upstate SC, USA
    Rituximab is also in clinical trials for MS to, I think. Not sure what phase, but if they found enough uses for a generic rituximab it might make it profitable for someone to go after a generic version.
     
  3. shannah

    shannah Senior Member

    Messages:
    862
    Likes:
    203
  4. Sherlock

    Sherlock tart cherry etc. for joints, insomnia

    Messages:
    1,136
    Likes:
    487
    Czechosherlockia, USA
    Unfortunately, AFAIK no one is allowed still to make generic versions of biologic medications, even when off patent in the U.S. as per the FDA. The rationale is that they are too difficult to make properly.


    http://www.businessweek.com/stories...siness-news-stock-market-and-financial-advice

    more here: http://www.merckmanuals.com/home/drugs/trade-name_and_generic_drugs/generic_biologic_drugs.html

    But then, Europe and Mabthera might be different?
     

See more popular forum discussions.

Share This Page